Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963272 | 0.86 | PPARG (0.39) | PPARAPPARGMEN1KMT2ATSHR | |
| SCHEMBL6964328 | 0.85 | FFAR1 (0.41) | PPARAPPARGTSHRFFAR1KDM4E | |
| Hydrochloric Acid SCHEMBL6964853 | 0.85 | PPARG (0.39) | PPARAPPARGMEN1KMT2ATSHR | |
| SCHEMBL6955014 | 0.83 | BCHE (0.41) | BCHEPPARAPPARGMEN1KMT2A | |
| SCHEMBL6959374 | 0.78 | ALDH1A1 (0.43) | PPARAMEN1KMT2ATSHRFFAR1 | |
| SCHEMBL6956018 | 0.76 | PPARG (0.40) | PPARAPPARGTSHRFFAR1 | |
| SCHEMBL27518219 | 0.75 | ALDH1A1 (0.36) | PPARAPPARGMEN1KMT2ATSHR | |
| SCHEMBL5099205 | 0.75 | FFAR1 (0.60) | PPARAPPARGFFAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6960508 | 0.74 | PPARG (0.39) | PPARAPPARGTSHRFFAR1 | |
| SCHEMBL6955024 | 0.74 | GAA (0.39) | BCHEMEN1KMT2ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-6166216-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6156748-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | BCHE 1135/4885PPARA 471/4885PPARG 458/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | BCHE 1135/4885PPARA 471/4885PPARG 458/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | BCHE 607/4885PPARA 902/4885PPARG 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.